B. Koplowitz

发表

Biphenylsulfonamide endothelin receptor antagonists. 4. Discovery of N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]- 2-yl]methyl]-N,3,3-trimethylbutanamide (BMS-207940), a highly potent and orally active ET(A) selective antagonist.

Ping Chen, S. Spergel, S. Chong, 2003, Journal of medicinal chemistry.

Eleven amino acid glucagon-like peptide-1 receptor agonists with antidiabetic activity.

K. Constantine, R. Stoffel, B. Koplowitz, 2009, Journal of medicinal chemistry.

Evaluation of Pharmacokinetics and Dose Proportionality of Diazepam After Intranasal Administration of NRL‐1 to Healthy Volunteers

A. Rabinowicz, B. Koplowitz, E. Carrazana, 2020, Clinical pharmacology in drug development.

Bioavailability and safety of diazepam intranasal solution compared to oral and rectal diazepam in healthy volunteers

R. Hogan, B. Koplowitz, E. Carrazana, 2020, Epilepsia.

In Vitro Characterization and Pharmacokinetics of Dapagliflozin (BMS-512148), a Potent Sodium-Glucose Cotransporter Type II Inhibitor, in Animals and Humans

W. Humphreys, B. Koplowitz, A. Khanna, 2010, Drug Metabolism and Disposition.

Design, synthesis, and structure-activity relationships of tetrahydroquinoline-based farnesyltransferase inhibitors.

J. Tokarski, B. Koplowitz, J. Hunt, 2005, Bioorganic & medicinal chemistry letters.

Absence of ethnic difference on single‐dose pharmacokinetics of rivoceranib between healthy male Caucasian, Japanese, and Chinese subjects

B. Koplowitz, Madhav Sachar, C. Park, 2020, Fundamental & clinical pharmacology.

Effect of caffeine on circulating theophylline levels in beagle dogs.

B. Koplowitz, F. Tse, K. H. Valia, 1981, Journal of pharmaceutical sciences.

Exploration of structure–activity relationships at the two C-terminal residues of potent 11mer Glucagon-Like Peptide-1 receptor agonist peptides via parallel synthesis

Christopher B. Cooper, B. Koplowitz, C. Mapelli, 2010, Peptides.

Pharmacokinetics of the Dipeptidyl Peptidase 4 Inhibitor Saxagliptin in Rats, Dogs, and Monkeys and Clinical Projections

W. Humphreys, L. Hamann, M. Kirby, 2009, Drug Metabolism and Disposition.

Pharmacokinetics of the Melanocortin Type 1 Receptor Agonist PL8177 After Subcutaneous Administration

B. Koplowitz, C. Spana, Luana Pesco Koplowitz, 2021, Drugs in R&D.

A selective small molecule agonist of the melanocortin‐1 receptor inhibits lipopolysaccharide‐induced cytokine accumulation and leukocyte infiltration in mice

J. Haycock, K. McIntyre, J. Macor, 2006, Journal of leukocyte biology.

Biorelevant In Vitro Skin Permeation Testing and In Vivo Pharmacokinetic Characterization of Lidocaine from a Nonaqueous Drug-in-Matrix Topical System

H. Maibach, D. Lissin, B. Koplowitz, 2021, AAPS PharmSciTech.

Effect of food intake on the pharmacokinetics of rivoceranib in healthy subjects

B. Koplowitz, Madhav Sachar, C. Park, 2021, Fundamental & clinical pharmacology.

Pharmacokinetics and Pharmacodynamics of Neffy (1 mg) compared to EpiPen (0.3 mg) and Manual IM injection (0.3 mg) – an Integrated Analysis

M. Kaliner, B. Koplowitz, M. Ebisawa, 2022, Journal of Allergy and Clinical Immunology.

Pharmacokinetics of muraglitazar (BMS-298585), a dual peroxisome proliferator-activated receptors (PPAR) alpha and gamma activator, in mice, rats, dogs, and monkeys.

W. Humphreys, B. Koplowitz, V. Hosagrahara, 2006, Xenobiotica; the fate of foreign compounds in biological systems.

Eleven amino acid glucagon-like peptide-1 receptor agonists with antidiabetic activity.

K. Constantine, R. Stoffel, B. Koplowitz, 2009, Journal of medicinal chemistry.